Bisphosphonates reduce costs-if women take them

Article

Osteoporosis-related health-care costs are lower for postmenopausal women prescribed bisphosphonates-if they comply with therapy. That is the conclusion of a retrospective analysis of prescription and treatment data presented at this year's NAMS meeting.

Osteoporosis-related health-care costs are lower for postmenopausal women prescribed bisphosphonates-if they comply with therapy. That is the conclusion of a retrospective analysis of prescription and treatment data presented at this year's NAMS meeting.

Data collected by Medstat and Medicare from more than 32,000 women aged 45 or older who filled a prescription for daily or weekly alendronate or risedronate were assessed. At the end of the 3-year study period, 37% of the women got their refills (compliant) and 21% had no gaps between bisphosphonate refills (persistence).

Mean costs of inpatient admissions were lower for those who were compliant and persistent-$10,653 and $9,846-versus noncompliant and nonpersistent-$14,074 and $13,601. Total mean health-care costs were $17,840 for women with on-time refills and $16,521 for women who took medication consistently, compared with $22,906 for those who missed refills and $22,219 for medication skippers.

Related Videos
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit: cdc.gov
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit: shrinerschildrens.org
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:  uofmhealth.org.
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
raanan meyer, md
New data shows elinzanetant's efficacy in treating menopausal symptoms | Image Credit: uvahealth.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.